In bladder cancer, the acquired mutation of isocitrate dehydrogenase 2 (IDH2) can induce reductive glutamine metabolism, stabilize the expression of HIF-1α, thus stimulate aerobic glycolysis and pentose phosphate pathway (PPP), and promote gemcitabine resistance 216. This evidence concerns the gene IDH2 and urinary bladder carcinoma.